Tag: sepsis

  • New COVID-19 Guidelines in Relation to Acute Coronary Syndrome and Sepsis

    New COVID-19 Guidelines in Relation to Acute Coronary Syndrome and Sepsis

    As the amount of available information and research into COVID-19 is constantly changing, we wish to continue to provide you with updated information.  Please find recent guidelines regarding COVID-19 and how it relates to acute coronary syndrome (ACS) and sepsis below.

    The Canadian Cardiovascular Society COVID-19 Rapid Response Team has recently released “COVID-19 and Cardiovascular Disease: What the Cardiac Healthcare Provider Should Know.1 Several interesting points that may be of interest include:

    • Myocardial injury defined as an elevation in troponin level is common (7-17%)
    • Troponin elevations are more common in severe illness vs non-severe and are associated with worse outcomes
    • Severe disease includes a subgroup of patients who reportedly develop a cytokine storm syndrome, including elevated NT-proBNP (27.5%), troponin (10%) and interleukin-6 levels
    • Recent data from Seattle suggests cardiomyopathy was common (7%), however patients had a high rate of prior congestive heart failure (42%)

    Additionally, a recent critical care guideline for the management of critically ill adults with COVID-192 has stated the following:

    • The prognosis of patients with COVID-19 and shock has not been systematically reported. In a study of 150 patients from 2 hospitals in Wuhan, China, shock was a major reason for death in 40%, and may, at least in part, be due to fulminant myocarditis.
    • Studies on risk factors associated with shock in patients with COVID-19 are lacking. The majority of those that are available report unadjusted estimates. Despite methodological limitations, these studies suggest that older age, comorbidities (especially diabetes and cardiovascular disease including hypertension), lower lymphocyte count, higher D-dimer level, and possibly cardiac injury are risk factors to consider.

    Please note, all studies mentioned in this COVID-19 update were not completed using RAMP products manufactured by Response Biomedical Corp.  RAMP products have not been evaluated specifically for use with COVID-19 patients.

    Please find the mentioned guidelines links below.

    1 Canadian Cardiovascular Society (2020). Guidance from the CCS COVID-19 Rapid Response Team. COVID-19 and Cardiovascular Disease: What the Cardiac Healthcare Provider Should Know. https://www.ccs.ca/images/Images_2020/COVID_and_Cardiovascular_Disease_22Mar2020.pdf

    2 Alhazzani, W., Møller, M. H., Arabi, Y. M., Loeb, M., Gong, M. N., Fan, E., … & Du, B. (2020). Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Medicine, 1-34 https://www.sccm.org/getattachment/Disaster/SSC-COVID19-Critical-Care-Guidelines.pdf?lang=en-US

  • Procalcitonin and D-dimer in Patients with COVID-19

    Procalcitonin and D-dimer in Patients with COVID-19

    As a medical device manufacturer, we have been closely monitoring the research that is currently being conducted into the detection of COVID-19.  Response Biomedical’s purpose is to save as many human lives as possible, and we strive to provide our channel partners with the most recent and relevant information.

    The following systematic literature review by Lippi and Plebani highlights the important abnormalities observed in patients with COVID-19.1 The review cites several papers which show increased Procalcitonin (PCT) and D-dimer levels in patients with a severe COVID-19 infection compared to those with milder symptoms.  In fact, a study conducted by Zhang et al. found that 25% of patients with COVID-19 who were admitted to the ICU had elevated PCT levels compared to 0% who were not admitted to the ICU.2  Furthermore, PCT can potentially be used prognostically as the progressive increase of its values seem to reflect a poorer outcome in patients with COVID-19.

    A meta-analysis of literature also performed by Lippi and Plebani shows an increase in PCT values associated with a nearly 5-fold higher risk of severe COVID-19 infection.3

    Please note, all studies mentioned in this COVID-19 update were not completed using RAMP products manufactured by Response Biomedical Corp.  RAMP products have not been evaluated specifically for use with COVID-19 patients.

    Please find the links to the mentioned articles below.

    1 Lippi, G., & Plebani, M. (2020). Laboratory abnormalities in patients with COVID-2019 infection. Clinical Chemistry and Laboratory Medicine (CCLM), (0), 20200198. https://www.degruyter.com/downloadpdf/j/cclm.ahead-of-print/cclm-2020-0198/cclm-2020-0198.pdf

    2 Zhang, J. J., Dong, X., Cao, Y. Y., Yuan, Y. D., Yang, Y. B., Yan, Y. Q., … & Gao, Y. D. (2020). Clinical characteristics of 140 patients infected by SARS‐CoV‐2 in Wuhan, China. Allergy. https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14238

    3 Lippi, G., & Plebani, M. (2020). Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis. Clinica Chimica Acta; International Journal of Clinical Chemistry. https://www.sciencedirect.com/science/article/pii/S0009898120301066?via%3Dihu